BioLineRx Ltd.
Giá mua
Cập nhật

BLRX-BREAKOUT-UPDATE

389
BLRX had a strong rally today and it's just getting started.

In the related idea my price target was $1.34.

Today's high was $1.78

Check out the weekly chart:

ảnh chụp nhanh

Photo Finish.

$1.34 was 1.618 extension level from Waves 1 & 2.

Since the price-action broke $1.34 we will have an extended 3rd wave.

I expect a very strong rally tomorrow, I will update in the morning before the open to confirm.

Target is hard to predict since its impossible to know what level extending waves will terminate.

I will keep a close eye on the price-action.

Will update.

-AB






Ghi chú
As expected, a very strong rally today!
Ghi chú
ảnh chụp nhanh
Ghi chú
We got a big runway...
Ghi chú
Reminder this is a WEEKLY chart...

Meaning this move is far from over...
Ghi chú
ảnh chụp nhanh
Ghi chú
Buckle up!
Ghi chú
ảnh chụp nhanh
Ghi chú
Target $2.24 (Sell Half)

Trade Price: 1.049
Ghi chú
ảnh chụp nhanh
Ghi chú
ảnh chụp nhanh
Ghi chú
Bull Flag
Ghi chú
BLRX will rally again tomorrow.
Ghi chú
ảnh chụp nhanh
Ghi chú
BLRX is about to rally again...
Ghi chú
BLRX continued to consolidate today.

Staying the course...
Ghi chú
ảnh chụp nhanh
Ghi chú
ảnh chụp nhanh
Ghi chú
Near-Term Target: $2.13
Ghi chú
ảnh chụp nhanh
Ghi chú
Primary Wave 1 Complete
Ghi chú
ảnh chụp nhanh
Ghi chú
03:21 PM EDT, 10/22/2018 (MT Newswires) -- Oppenheimer has kept its outperform rating on BioLineRx (BLRX) with a price target of $3, betting on BL-8040's commercial opportunity as a stem cell mobilizer after top-line data from the COMBAT/KEYNOTE-202 trial of BL-8040 in combination with pembrolizumab in advanced pancreatic cancer showed modest response rate.
"Given the combination's favorable safety profile, BioLineRx and Merck (MRK) are testing a triplet combination including chemotherapy in an effort to increase response rate," analyst Mark Breidenbach said in a note.
"While we believe the triplet combination is worth testing, our valuation of BioLineRx still remains focused on BL-8040's commercial opportunity as a stem cell mobilizer."
Ghi chú
ảnh chụp nhanh
Ghi chú
ảnh chụp nhanh
Ghi chú
Breakout Imminent
Ghi chú
ảnh chụp nhanh

Thông báo miễn trừ trách nhiệm

Thông tin và các ấn phẩm này không nhằm mục đích, và không cấu thành, lời khuyên hoặc khuyến nghị về tài chính, đầu tư, giao dịch hay các loại khác do TradingView cung cấp hoặc xác nhận. Đọc thêm tại Điều khoản Sử dụng.